Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
downgraded at Jefferies from Buy to Hold. $17 price target. Stock is largely pricing in FDA approval of Bydureon.
downgraded at Barclays to Equal Weight from Overweight. After announcing solid 4Q10 results, the company said to expect significant near-term enrollment declines. Price target sunk to $44 from $66.
downgraded at FBR from Market Perform to Underperform. $40 price target. Company could continue to see lower enrollment rates and earnings for the next several years.
upgraded at UBS from Sell to Neutral. $11 price target. Checks suggest modest optimism for builders in Phoenix and Washington DC.
upgraded at Deutsche to Buy from Hold. $19.50 price target. Demand trends remain positive and the company can continue to gain market share.
upgraded at UBS from Neutral to Buy. $9.50 price target. Company offers an attractive 8.7% dividend yield.
downgraded at Barclays to Equal Weight from Overweight as the company guided for slightly lower December revenues and bookings. Price target trimmed to $33 from $35. 2011 and 2012 EPS estimates set at $2.36 and $2.38, respectively.
numbers lowered at Morgan Stanley through 2012. Inventory is likely to grow in the coming quarters. Overweight rating and new $32 price target.
estimates increased at UBS through 2012. Company should continue to see higher demand from communications and industrial customers. Neutral rating and $31 price target.
upgraded at BMO from Market Perform to Outperform. $18 price target. Trends are improving in Las Vegas.
upgraded at UBS from Sell to Neutral. $8.50 price target. Recent checks suggest that a gradual housing recovery is possible over the next 12-24 months.
rated new Market Perform at FBR Capital Markets. $30 price target. Stock offers a 5% dividend yield, but 2011 earnings could be disappointing.
rated new Buy at Jefferies. $34 price target. Company is diversifying its growth, by expanding overseas.
downgraded at Morgan Keegan from Outperform to Market Perform. Valuation call, as the stock is up 20% since late August.
rated new Hold at ThinkEquity. $14 price target. Stock appears cheap, but the company has leverage to lower PC demand.
rated new Buy at Deutsche Bank. $42 price target. Company trades below its average historical valuation, but can deliver 17% annual sales growth over the next couple of years.
upgraded at Deutsche from Hold to Buy. Company has strong earnings momentum and should continue to deliver organic growth. $52 price target.
STOCK COMMENTS / EPS CHANGES
estimates, target raised at Jefferies. Shares of ADTN now seen reaching $34. Estimates also increased, given continued strong demand. Hold rating.
estimates upped at Goldman through 2012. Company should benefit from a weaker dollar and its share buyback program. Buy rating.
estimates, target raised at Goldman. Shares of CSX now seen reaching $34. Estimates also increased, given higher realized margins. Sell rating.
estimates higher at Credit Suisse. EBAY 2010 and 2011 EPS estimates jumped to $1.66 and $1.96, respectively. eBay's Marketplaces GMV should be able to grow at a decent rate. Maintain Outperform rating and $32 price target.
target increased at Jefferies to $21. Company can exceed low expectations for Tomosynthesis. Buy rating.
estimates increased at Goldman through 2012. Company should benefit from better credit trends. Buy rating and $51 price target.
numbers raised at UBS. Shares of KO now seen reaching $65. Estimates also increased, given better demand in emerging markets and the U.S. Buy rating.
target, estimates cut at Barclays. LMT price target lowered to $76 from $81. 2010 and 2011 EPS estimates reduced to $6.90 and $7, respectively. Adjusting numbers for sale of EIG for $815 million. Maintain Equal Weight rating.
added to Conviction Buy List at Goldman Sachs. Company is moving to the NYSE and should benefit from lower natural gas prices. New $34 price target.
numbers boosted at Morgan Stanley. Shares of MO now seen reaching $62. Estimates also upped, given the weaker dollar and potential for share buybacks. Overweight rating.
price target cut at Credit Suisse to $36 from $40 on softness in PC sales. Maintain Outperform rating.
estimates lowered at Goldman through 2011. Company likely to see lower cash trading revenue. Neutral rating and $31 price target.
estimates lowered at Goldman through 2012. Company is likely to post lower glass volumes and is facing higher pension and interest costs. Neutral rating.
numbers boosted at Goldman. Shares of PENN now seen reaching $25. Estimates also upped, given new table games at WV and PA locations. Sell rating.
estimates, target boosted at UBS. Shares of SBUX now seen reaching $31. Estimates also upped, given higher retail sales expectations. Buy rating.
estimates, target upped at UBS. VFC estimates were boosted through 2011. Company should see higher demand for North Face and benefit from recent currency trends. Buy rating and new $98 price target.
This article was written by a staff member of TheStreet.